(Q41133430)

27 September 2017

1 reference

title

Effects of antirheumatic agents on cytokines (English)

1 reference

27 September 2017

Barrera P

1

1 reference

27 September 2017

Boerbooms AM

series ordinal

2

1 reference

27 September 2017

van de Putte LB

series ordinal

3

1 reference

27 September 2017

van der Meer JW

series ordinal

4

1 reference

27 September 2017

publication date

1 February 1996

1 reference

Seminars in Arthritis and Rheumatism

27 September 2017

published in

1 reference

27 September 2017

volume

25

1 reference

27 September 2017

issue

4

1 reference

27 September 2017

page(s)

234-253

1 reference

Antirheumatic drugs: a proposed new classification

27 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980035-7

7 January 2021

Inhibition of the production and effects of interleukin-1 and tumor necrosis factor alpha in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980035-7

7 January 2021

Role of interleukin-1, tumor necrosis factor alpha, and interleukin-6 in cartilage proteoglycan metabolism and destruction. Effect of in situ blocking in murine antigen- and zymosan-induced arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980035-7

7 January 2021

The type II 'decoy' receptor: a novel regulatory pathway for interleukin 1.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980035-7

7 January 2021

Cytokines in chronic inflammatory arthritis. I. Failure to detect T cell lymphokines (interleukin 2 and interleukin 3) and presence of macrophage colony-stimulating factor (CSF-1) and a novel mast cell growth factor in rheumatoid synovitis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980035-7

7 January 2021

Peripheral blood and synovial fluid monocyte activation in inflammatory arthritis. II. Low levels of synovial fluid and synovial tissue interferon suggest that gamma-interferon is not the primary macrophage activating factor

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980035-7

7 January 2021

Interleukin 13, an interleukin 4-like cytokine that acts on monocytes and B cells, but not on T cells

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980035-7

7 January 2021

The IL-2/IL-2 receptor system: a target for rational immune intervention

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980035-7

7 January 2021

The soluble interleukin-2 receptor: biology, function, and clinical application

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980035-7

7 January 2021

Modalities for reducing interleukin 1 activity in disease

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980035-7

7 January 2021

Effect of antiinflammatory drugs on human interleukin-1-induced cartilage degradation

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980035-7

7 January 2021

The effect of second-line antirheumatic drugs on interleukin-8 mRNA synthesis and protein secretion in human endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980035-7

7 January 2021

The clinical significance of autoantibody profiles in patients with systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980035-7

7 January 2021

Alteration of interleukin-1 activity and the acute phase response in adjuvant arthritic rats treated with disease modifying antirheumatic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980035-7

7 January 2021

Effect of auranofin and sodium aurothiomalate on interleukin-1 production from human monocytes in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980035-7

7 January 2021

Suppressive effect of anti-rheumatic drugs on interleukin-1 beta release from human peripheral blood monocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980035-7

7 January 2021

The effect of gold sodium thiomalate and auranofin on lipopolysaccharide-induced interleukin-1 production by blood monocytes in vitro: variation in healthy subjects and patients with arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980035-7

7 January 2021

Aurothioglucose inhibits induced NF-kB and AP-1 activity by acting as an IL-1 functional antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980035-7

7 January 2021

The effect of gold treatment on monocyte interleukin-1 production in rheumatoid arthritis. A prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980035-7

7 January 2021

Increased IL-1 receptor antagonist (IL-1ra) production and decreased IL-1 beta/IL-1ra ratio in mononuclear cells from rheumatoid arthritis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980035-7

7 January 2021

Monocyte chemoattractant protein 1 and interleukin 8 production by rheumatoid synoviocytes. Effects of anti-rheumatic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980035-7

7 January 2021

Interleukin-8 in inflammatory rheumatic diseases: synovial fluid levels, relation to rheumatoid factors, production by mononuclear cells, and effects of gold sodium thiomalate and methotrexate

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980035-7

7 January 2021

Pharmacologic modulation of TNF production by endotoxin stimulated macrophages: in vitro and in vivo effects of auranofin and other chrysotherapeutic compounds

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980035-7

7 January 2021

Production of interleukin-6 by monocytes isolated from rheumatoid arthritis patients receiving second-line drug therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980035-7

7 January 2021

Intramuscular gold decreases cytokine expression and macrophage numbers in the rheumatoid synovial membrane

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980035-7

7 January 2021

Rheumatoid arthritis: opposing actions of haemopoietic growth factors and slow-acting anti-rheumatic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980035-7

7 January 2021

Suppression of interleukin-2 and interleukin-2 receptor biosynthesis by gold compounds in in vitro activated human peripheral blood mononuclear cells

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980035-7

7 January 2021

Sodium aurothiomalate inhibits T cell responses to interleukin-2

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980035-7

7 January 2021

Inhibition of in vitro proliferative response of cultured T lymphocytes to interleukin-2 by gold sodium thiomalate

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980035-7

7 January 2021

The interaction of auranofin and buthionine sulfoximine blocks activation of human peripheral T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980035-7

7 January 2021

In vitro effects of two gold compounds, and D-penicillamine on the production of interferon gamma

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980035-7

7 January 2021

Effects of gold sodium thiomalate on interferon stimulation of C2 synthesis and HLA-DR expression by human monocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980035-7

7 January 2021

Serum concentrations of soluble interleukin 2 receptor in patients with rheumatoid arthritis: effect of second line drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980035-7

7 January 2021

Comparative inhibitory effects of bucillamine and D-penicillamine on the function of human B cells and T cells

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980035-7

7 January 2021

Inhibition of T cell-dependent antibody production by D-penicillamine. Different requirements for Cu2+ in suppression of polyclonal and antigen-specific B cell responses

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980035-7

7 January 2021

Effect of antiarthritic drugs on the enhanced interleukin-1 (IL-1) production by macrophages from adjuvant-induced arthritic (AA) rats

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980035-7

7 January 2021

Covalent disulfide binding of human IL-1β to α2-macroglobulin: Inhibition by d-penicillamine

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980035-7

7 January 2021

Suppression of human fibroblast proliferation by D-penicillamine and copper sulfate in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980035-7

7 January 2021

Inhibition of human endothelial cell proliferation in vitro and neovascularization in vivo by D-penicillamine

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980035-7

7 January 2021

Regulation of B cell function by bucillamine, a novel disease-modifying antirheumatic drug

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980035-7

7 January 2021

Salicylazosulfapyridine (Salazopyrin) effect on endotoxin-induced production of interleukin-1-like factor from human monocytes in vitro.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980035-7

7 January 2021

Sulfasalazine inhibits the binding of TNF alpha to its receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980035-7

7 January 2021

Circulating cytokine levels in patients with rheumatoid arthritis: results of a double blind trial with sulphasalazine

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980035-7

7 January 2021

The effect of salazosulfapyridine on the in vitro antibody production in murine spleen cells

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980035-7

7 January 2021

IL-6 and soluble IL-2 receptor in rheumatoid arthritis patients treated with second line drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980035-7

7 January 2021

Combination of methotrexate and sulphasalazine vs methotrexate alone: a randomized open clinical trial in rheumatoid arthritis patients resistant to sulphasalazine therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980035-7

7 January 2021

Effect of methotrexate alone or in combination with sulphasalazine on the production and circulating concentrations of cytokines and their antagonists. Longitudinal evaluation in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980035-7

7 January 2021

Methotrexate: mechanism of action in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980035-7

7 January 2021

The effects of methotrexate on the production and activity of interleukin-1

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980035-7

7 January 2021

Rescue of interleukin-1 activity by leucovorin following inhibition by methotrexate in a murine in vitro system

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980035-7

7 January 2021

Mechanisms of methotrexate action in rheumatoid arthritis. Selective decrease in synovial collagenase gene expression

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980035-7

7 January 2021

Methotrexate in rheumatoid arthritis: studies with animal models

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980035-7

7 January 2021

Circulating concentrations and production of cytokines and soluble receptors in rheumatoid arthritis patients: effects of a single dose methotrexate

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980035-7

7 January 2021

Reduction of leukocyte and interleukin-1 beta concentrations in the synovial fluid of rheumatoid arthritis patients treated with methotrexate

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980035-7

7 January 2021

Circulating soluble tumor necrosis factor receptors, interleukin-2 receptors, tumor necrosis factor alpha, and interleukin-6 levels in rheumatoid arthritis. Longitudinal evaluation during methotrexate and azathioprine therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980035-7

7 January 2021

Paradoxical enhancement of interleukin-2-mediated cytotoxicity against K562 cells by addition of a low dose of methotrexate

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980035-7

7 January 2021

Increased polyamines may downregulate interleukin 2 production in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980035-7

7 January 2021

Interleukin-2 receptor levels in the sera of rheumatoid arthritis patients treated with methotrexate

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980035-7

7 January 2021

Serial measurements of soluble interleukin 2 receptor levels (sIL2-R) in children with juvenile rheumatoid arthritis treated with oral methotrexate

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980035-7

7 January 2021

Differential in vitro actions of cyclosporin, methylprednisolone, and 6-mercaptopurine: implications for drugs' influence on lymphocyte activation mechanisms

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980035-7

7 January 2021

Effect of interleukin-2 on the inhibition of the human mixed lymphocyte reaction (MLR) by azathioprine

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980035-7

7 January 2021

The Effect of Azathioprine on Serum Levels of Interleukin 6 and Soluble Interleukin 2 Receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980035-7

7 January 2021

The T-cell transcription factor NFATp is a substrate for calcineurin and interacts with Fos and Jun

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980035-7

7 January 2021

Calcineurin mediates human tumor necrosis factor alpha gene induction in stimulated T and B cells

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980035-7

7 January 2021

Immunologic parameters of response in patients with rheumatoid arthritis treated with cyclosporin A

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980035-7

7 January 2021

Effect of cyclosporin A on interleukin-6 and soluble interleukin-2 receptor in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980035-7

7 January 2021

Cyclosporin treatment in rheumatoid arthritis is associated with an increased serum activity of beta-glucuronidase

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980035-7

7 January 2021

Plasma interleukin-2 and a soluble/shed interleukin-2 receptor in serum of patients with Crohn's disease. Effect of cyclosporin

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980035-7

7 January 2021

Cyclosporine in systemic sclerosis. Results of a forty-eight-week open safety study in ten patients

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980035-7

7 January 2021

Effects of glucocorticoids in rheumatoid arthritis. Diminished glucocorticoid receptors do not result in glucocorticoid resistance.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980035-7

7 January 2021

A conserved AU sequence from the 3' untranslated region of GM-CSF mRNA mediates selective mRNA degradation

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980035-7

7 January 2021

Dexamethasone inhibition of interleukin 1 beta production by human monocytes. Posttranscriptional mechanisms

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980035-7

7 January 2021

Control of cachectin (tumor necrosis factor) synthesis: mechanisms of endotoxin resistance.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980035-7

7 January 2021

Glucocorticoids inhibit the production of IL6 from monocytes, endothelial cells and fibroblasts

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980035-7

7 January 2021

The effects of hydrocortisone on in vitro lymphocyte proliferation and interleukin-2 and -4 production in corticosteroid sensitive and resistant subjects.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980035-7

7 January 2021

Induction of high-affinity interleukin 1 receptor on human peripheral blood lymphocytes by glucocorticoid hormones

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980035-7

7 January 2021

Reduction of tumor necrosis factor ? and interleukin-1? levels in human synovial tissue by interleukin-4 and glucocorticoid

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980035-7

7 January 2021

Reduction of toxicity of interleukin-2 and lymphokine-activated killer cells in humans by the administration of corticosteroids

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980035-7

7 January 2021

Corticosteroid inhibition of the OKT3-induced cytokine-related syndrome--dosage and kinetics prerequisites

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980035-7

7 January 2021

Prednisolone treatment in asthma is associated with modulation of bronchoalveolar lavage cell interleukin-4, interleukin-5, and interferon-gamma cytokine gene expression

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980035-7

7 January 2021

Effect of corticosteroid treatment on interleukin-1 and tumour necrosis factor secretion by monocytes from subjects with asthma.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980035-7

7 January 2021

Correlation of interleukin-6 production and disease activity in polymyalgia rheumatica and giant cell arteritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980035-7

7 January 2021

Serum interleukin-2-receptor in rheumatoid arthritis: a prognostic indicator of disease activity?

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980035-7

7 January 2021

Tumour necrosis factor alpha and interleukin-2 in plasma from rheumatoid arthritis patients in relation to disease activity

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980035-7

7 January 2021

IX 207-887 in rheumatoid arthritis. A double-blind placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980035-7

7 January 2021

Regulation of human normal and osteoarthritic chondrocyte interleukin-1 receptor by antirheumatic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980035-7

7 January 2021

Rheumatoid arthritis treated with tenidap and piroxicam. Clinical associations with cytokine modulation by tenidap

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980035-7

7 January 2021

The use of immunomodulators in early rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980035-7

7 January 2021

New therapeutic approaches in autoimmune rheumatic diseases, with special emphasis on rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980035-7

7 January 2021

Molecular mechanism of interleukin-8 gene expression

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980035-7

7 January 2021

Induction of antinuclear antibodies in patients with rheumatoid arthritis receiving treatment with human recombinant interferon gamma

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980035-7

7 January 2021

Recombinant interferon-gamma in the treatment of systemic sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980035-7

7 January 2021

Treatment of systemic sclerosis with gamma-interferon

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980035-7

7 January 2021

Hematopoietic growth factors in rheumatoid arthritis: a critical approach to their use in view of possible adverse effects

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980035-7

7 January 2021

Granulocyte colony-stimulating factor induction of improved leukocytopenia with inflammatory flare in a Felty's syndrome patient

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980035-7

7 January 2021

Interleukin-6 antibodies in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980035-7

7 January 2021

Beneficial effect of monoclonal antibody to interleukin 2 receptor on activated T cells in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980035-7

7 January 2021

DAB486IL-2 fusion toxin in refractory rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980035-7

7 January 2021

Interleukin-2 diphtheria fusion protein (DAB486IL-2) in refractory rheumatoid arthritis. A double-blind, placebo-controlled trial with open-label extension.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980035-7

7 January 2021

Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980035-7

7 January 2021

Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980035-7

7 January 2021

Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980035-7

7 January 2021

The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980035-7

7 January 2021

Cyclosporin A. Mode of action and effects on bone and joint tissues

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980035-7

7 January 2021

10.1016/S0049-0172(96)80035-7

Identifiers

DOI

1 reference

27 September 2017

1 reference